KZIA - Kazia Growth-Adjusted Payback Ratio

Symbol and logo of brand Kazia Therapeutics (KZIA)

Kazia Therapeutics focuses its innovative activity on brain tumor therapy through international clinical platforms for paxalisib. Business development relies on strategic alliances and the acquisition of inhibitor patents. The company creates molecules that cross the blood-brain barrier to treat aggressive forms of cancer. Analyzing the growth-normalized P/E, we see that the value is fixed at 0.00, which helps objectively assess the risks of asset undervaluation.

KZIA Kazia Price/Earnings to Growth Ratio (07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for Kazia Therapeutics (KZIA)

- current price and projected stock value:
Fundamental company analysis:Kazia Therapeutics KZIA
Original product of Kazia

This metric correlates the P/E market multiple with earnings growth rates, allowing for the identification of undervalued assets with high expansion potential at values below one. By analyzing the PEG ratio, an investor can see how geopolitical barriers and biomaterial logistics disruptions are slowing the clinical trials of Kazia Therapeutics (KZIA), directly reducing the projected growth rate and adjusting the company's fundamental value.